Status:
RECRUITING
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
Lead Sponsor:
Jinling Hospital, China
Conditions:
Irritable Bowel Syndrome with Diarrhea
Purine Metabolism Disorder
Eligibility:
All Genders
16-80 years
Phase:
EARLY_PHASE1
Brief Summary
This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. ...
Eligibility Criteria
Inclusion
- Patients are diagnosed with IBS. IBS was diagnosed based on the Rome IV criteria. Subjects aged from 16-80 years old without any gut medical conditions like inflammatory bowel diseases, infectious diarrhea, colon tumors were included.
Exclusion
- Subjects who are taking any probiotics, PPIs, antibiotics or any drugs affecting uric acid levels for at least one month before the study.
- Subjects who decline to participate into the study.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06612411
Start Date
June 1 2024
End Date
December 31 2024
Last Update
September 25 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinling Hospital
Nanjing, China
2
Jinling Hospital
Nanjing, China